These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.
TheStreet Senior Columnist Adam Feuerstein responded to an article in the Boston Business Journal which suggested that Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) could be taken over by any number of companies.
The potential suitors were thought to include Roche Holding Ltd. (ADR) (OTC: RHHBY), Celgene Corporation (NASDAQ: CELG), Gilead Sciences, Inc. (NASDAQ: GILD), Amgen, Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).
Feuerstein, however, thought that a takeover by those companies would not be likely as “it doesn’t really fit their strategy in terms of business development strategy or M&A strategy.”
Feuerstein added that the company might be a takeover candidate at some point, just not by the above companies, especially since it has a small market cap at its current valuation.
Ariad Pharmaceuticals traded at $8.95, down 1.65 percent.
Check out the full interview below. Feuerstein comes in at about the one-hour mark:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Adam Feuerstein Boston Business Journal TheStreetBiotech Exclusives Trading Ideas Interview General
